Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
In the latest session, Kymera Therapeutics Inc (NASDAQ: KYMR) closed at $66.23 up 0.36% from its previous closing price of $65.99. In other words, the price has increased by $0.36 from its previous closing price. On the day, 0.74 million shares were traded. KYMR stock price reached its highest trading level at $68.77 during the session, while it also had its lowest trading level at $65.24.
Ratios:
For a deeper understanding of Kymera Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.38 and its Current Ratio is at 7.38. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.07.
On October 24, 2025, B. Riley Securities reiterated its Buy rating and also lowered its target price recommendation from $60 to $80.
On October 21, 2025, Mizuho started tracking the stock assigning a Outperform rating and target price of $81.Mizuho initiated its Outperform rating on October 21, 2025, with a $81 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Oct 29 ’25 when Mainolfi Nello sold 30,000 shares for $60.99 per share. The transaction valued at 1,829,737 led to the insider holds 660,482 shares of the business.
Mainolfi Nello bought 30,000 shares of KYMR for $1,850,400 on Oct 29 ’25. On Oct 15 ’25, another insider, Gollob Jared, who serves as the Chief Medical Officer of the company, sold 59,576 shares for $61.42 each. As a result, the insider received 3,659,254 and left with 109,992 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KYMR now has a Market Capitalization of 4765184000 and an Enterprise Value of 4343499264. For the stock, the TTM Price-to-Sale (P/S) ratio is 108.97 while its Price-to-Book (P/B) ratio in mrq is 5.02. Its current Enterprise Value per Revenue stands at 99.314 whereas that against EBITDA is -13.509.
Stock Price History:
The Beta on a monthly basis for KYMR is 2.23, which has changed by 0.41397047 over the last 52 weeks, in comparison to a change of 0.12469888 over the same period for the S&P500. Over the past 52 weeks, KYMR has reached a high of $68.80, while it has fallen to a 52-week low of $19.44. The 50-Day Moving Average of the stock is 8.66%, while the 200-Day Moving Average is calculated to be 51.15%.
Shares Statistics:
For the past three months, KYMR has traded an average of 756.85K shares per day and 678280 over the past ten days. A total of 71.74M shares are outstanding, with a floating share count of 59.57M. Insiders hold about 17.20% of the company’s shares, while institutions hold 97.75% stake in the company. Shares short for KYMR as of 1763078400 were 8581283 with a Short Ratio of 11.34, compared to 1760486400 on 8118708. Therefore, it implies a Short% of Shares Outstanding of 8581283 and a Short% of Float of 14.7.
Earnings Estimates
The company has 21.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is -$0.98, with high estimates of -$0.76 and low estimates of -$1.37.
Analysts are recommending an EPS of between -$2.77 and -$3.86 for the fiscal current year, implying an average EPS of -$3.48. EPS for the following year is -$3.82, with 21.0 analysts recommending between -$2.99 and -$6.0.
Revenue Estimates
A total of 21 analysts believe the company’s revenue will be $14.63M this quarter.It ranges from a high estimate of $52.24M to a low estimate of $3M. As of. The current estimate, Kymera Therapeutics Inc’s year-ago sales were $7.39MFor the next quarter, 21 analysts are estimating revenue of $10.55M. There is a high estimate of $20M for the next quarter, whereas the lowest estimate is $5M.
A total of 22 analysts have provided revenue estimates for KYMR’s current fiscal year. The highest revenue estimate was $105M, while the lowest revenue estimate was $39M, resulting in an average revenue estimate of $53.37M. In the same quarter a year ago, actual revenue was $47.07MBased on 22 analysts’ estimates, the company’s revenue will be $47.38M in the next fiscal year. The high estimate is $100M and the low estimate is $10M.
